This inventor holds 43 USPTO granted patents, primarily in Thrombomodulin Variants. Top assignees: Eli Lilly and Company, Indiana University. Active years: 1991-2011.
Company Filing History:
43 out of 4,508Â 
1 out of 804Â 
Years Active: 1991-2011
Areas of Expertise:
Title: **Brian W Grinnell: Pioneering Innovations in Renal Treatment**
Introduction
Brian W Grinnell, based in Indianapolis, IN, is a notable inventor with an impressive portfolio of 43 patents. His contributions to the field of medical innovation, particularly in the treatment of renal issues, have made significant impacts on healthcare practices.
Latest Patents
Among his latest patents, two stand out for their groundbreaking approaches to renal failure treatment. The first patent addresses a novel method for treating acute renal failure using soluble thrombomodulin variants. This invention outlines a technique for preventing and treating renal failure caused by various conditions, utilizing soluble thrombomodulin that does not activate Protein C. This innovative method aims to prevent or reduce acute kidney injury alongside standard care, thus enhancing patient outcomes.
The second patent involves methods of treating diseases with activated protein C. This method focuses on using activated protein C to directly regulate the expression of specific genes associated with various diseases or pathological conditions, showcasing Grinnell's commitment to advancing medical science through effective therapeutic interventions.
Career Highlights
Throughout his distinguished career, Brian W Grinnell has collaborated with renowned institutions such as Eli Lilly and Company and the Indiana University Research and Technology Corporation. His work has not only propelled his own career but has also contributed to advancements in the pharmaceutical and research landscape.
Collaborations
Grinnell has worked alongside esteemed colleagues, including David Thompson Berg and Mark Alan Richardson, further demonstrating the collaborative nature of innovation in the medical field. These partnerships have facilitated the exchange of ideas and expertise, enhancing the development of his patented technologies.
Conclusion
Brian W Grinnell's career exemplifies the essence of innovation within the medical sector. His extensive patent portfolio, coupled with his collaborative efforts, positions him as a key figure in advancing treatments for renal conditions. His contributions not only pave the way for future research but also significantly improve patient care and outcomes in healthcare.